ENGAGE AF-TIMI 48 试验:房颤患者体重指数与结局的关系
在 ENGAGE AF-TIMI 48 试验的 21 028 例房颤患者中,按 BMI 分层分析显示,BMI 每增加 5 kg/m2 与卒中/体循环栓塞风险降低(HR 0.88)和死亡风险降低(HR 0.91)独立相关,但与大出血风险增加(HR 1.06)相关。艾多沙班与华法林在各 BMI 组中的疗效和安全性相似。
要点
- BMI 升高与房颤患者卒中/体循环栓塞及死亡风险降低独立相关。
- BMI 升高同时与大出血及临床相关非大出血风险增加相关。
- 艾多沙班与华法林在不同 BMI 组间的疗效和安全性相似。
核心结论
- BMI 升高独立关联卒中/体循环栓塞风险降低和生存改善,但出血风险增加。
- 艾多沙班在各 BMI 组(18.5 至 >40 kg/m2)的疗效与安全性特征相似。
研究设计与样本
- ENGAGE AF-TIMI 48 试验的队列分析,共纳入 21 028 例房颤患者。
- 患者随机接受华法林(INR 2.0-3.0)或艾多沙班治疗,按 BMI 分类:低体重(<18.5)0.8%、正常(18.5 至 <25)21.4%、超重(25 至 <30)37.6%、中度肥胖(30 至 <35)24.8%、重度肥胖(35 至 <40)10.0%、极重度肥胖(≥40)5.5%。
主要发现
- BMI 每增加 5 kg/m2,卒中/体循环栓塞风险 HR 0.88(P = 0.0001),缺血性卒中/体循环栓塞 HR 0.87(P < 0.0001),死亡 HR 0.91(P < 0.0001)。
- BMI 每增加 5 kg/m2,大出血风险 HR 1.06(P = 0.025),大出血或临床相关非大出血 HR 1.05(P = 0.0007)。
- 性别与 BMI 分类存在显著交互作用,男性缺血性卒中/体循环栓塞风险降低,女性出血风险增加。
- BMI >18.5 kg/m2 各组间艾多沙班谷浓度和抗 Xa 活性相似,华法林治疗窗内时间随 BMI 增加显著改善(P < 0.0001)。
临床怎么用
- 房颤患者评估卒中和出血风险时应考虑 BMI,高 BMI 患者可能卒中风险较低但出血风险较高。
- 艾多沙班在不同 BMI 组间的疗效和安全性相似,支持其在此类人群中的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the relationship between body mass index (BMI) and outcomes in patients with atrial fibrillation (AF). METHODS AND RESULTS: In the ENGAGE AF-TIMI 48 trial, patients with AF were randomized to warfarin (international normalized ratio 2.0-3.0) or edoxaban. The cohort (N = 21 028) included patients across BMI categories (kg/m2): underweight (<18.5) in 0.8%, normal (18.5 to <25) in 21.4%, overweight (25 to <30) in 37.6%, moderately obese (30 to <35) in 24.8%, severely obese (35 to <40) in 10.0%, and very severely obese (≥40) in 5.5%. In an adjusted analysis, higher BMI (continuous, per 5 kg/m2 increase) was significantly and independently associated with lower risks of stroke/systemic embolic event (SEE) [hazard ratio (HR) 0.88, P = 0.0001], ischaemic stroke/SEE (HR 0.87, P < 0.0001), and death (HR 0.91, P < 0.0001), but with increased risks of major (HR 1.06, P = 0.025) and major or clinically relevant non-major bleeding (HR 1.05, P = 0.0007). There was a significant interaction between sex and increasing BMI category, with lower risk of ischaemic stroke/SEE in males and increased risk of bleeding in women. Trough edoxaban concentration and anti-Factor Xa activity were similar across BMI groups >18.5 kg/m2, while time in therapeutic range for warfarin improved significantly as BMI increased (P < 0.0001). The effects of edoxaban vs. warfarin on stroke/SEE, major bleeding, and net clinical outcome were similar across BMI groups. CONCLUSION: An increased BMI was independently associated with a lower risk of stroke/SEE, better survival, but increased risk of bleeding. The efficacy and safety profiles of edoxaban were similar across BMI categories ranging from 18.5 to >40.
引用
- Boriani G, Ruff CT, Kuder JF, et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019. PMID: 30624719. doi:10.1093/eurheartj/ehy861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。